Objectives: Suppressive herpes simplex virus (HSV) therapy can decrease plasma, cervical, and rectal HIV-1 levels in HIV-1/HSV-2 co-infected persons. We evaluated the effect of HSV-2 suppression on seminal HIV-1 levels.
Introduction
The earliest studies of interactions between herpes simplex virus (HSV)-2 and HIV-1 infections were from the 1980s, including among men who have sex with men (MSM) [1] . Recently, several studies have shown that daily suppressive antiviral therapy for HSV reduces plasma, cervical and rectal HIV-1 levels in HIV-1 and HSV-2 infected adults [2] [3] [4] [5] ; a clinical trial to assess the efficacy of this approach for reduction of sexual transmission of HIV-1 is ongoing [6] . Plasma HIV-1 level has been demonstrated to be a significant biologic marker of HIV-1 transmission risk from an HIV-infected partner [7, 8] . Semen is the main biologic fluid for exposure from HIV-infected men to their female and male partners during insertive sex [9] . However, a direct relationship between seminal HIV-1 level and transmission has not been shown in part due to difficulties in conducting sufficiently large, prospective studies of HIV-1 discordant couples with collection of blood and genital samples [7] .
HIV-1 transmission is related to many factors [10] , and reductions in plasma and seminal HIV-1 levels may lead to reduced HIV-1 infectiousness. Although prior studies have demonstrated that HSV suppression reduces plasma, cervical, and rectal HIV-1 levels, no studies have assessed the effect of HSV suppression on seminal HIV-1 levels. We evaluated seminal HIV-1 levels in a randomized, double-blind, placebo-controlled crossover trial among HIV-1/HSV-2 co-infected MSM that demonstrated a mean 0.33 log 10 reduction in plasma HIV-1 during twice daily suppressive valacyclovir [3] .
Methods

Study characteristics
Study design As previously described [3] , a randomized, double-blind, placebo-controlled crossover trial of valacyclovir for HSV and HIV-1 suppression was conducted in Lima, Peru. Briefly, participants were MSM who were !18 years old, were seropositive for HIV-1 and HSV-2, had no history of antiretroviral use, and had a CD4 cell count !200 cells/ml per Peruvian guidelines for antiretroviral therapy (ART) initiation at the time of study implementation [3] . Exclusion criteria included current or planned therapy with antiretrovirals or antivirals for HSV (acyclovir, famciclovir, or valacyclovir), a history of adverse reactions to these antivirals, a history of seizures, a serum creatinine level !2.0 mg/dl, or hematocrit 30%.
The human experimentation guidelines of the US Department of Health and Human Services and the individual institutions were followed in the conduct of the clinical research. The institutional review boards of the University of Washington and the Asociación Civil Impacta Salud y Educación approved the protocol.
Study medication
Valacyclovir (500 mg orally twice daily) and matching placebo were supplied by GlaxoSmithKline. As previously described [3] , participants were randomly assigned 1 : 1 (valacyclovir to placebo) in blocks of 10. After 8 weeks of the initial treatment, each participant crossed over to the alternative treatment for 8 weeks, separated by a 2-week washout period with daily placebo. Open-label valacyclovir (1 g orally twice daily for 3 days) was dispensed for symptomatic herpes recurrences. Four men were treated with open-label valacyclovir for genital herpes recurrences during the study, of which three occurred during placebo administration.
Study procedures
At enrollment, participants underwent a physical exam, and had blood, semen, and HSV swabs collected. Participants came to clinic three times a week. In addition to anoscopy samples for HIV-1 and HSV, and blood draws reported previously, weekly semen samples were collected into sterile containers by study participants either just prior to the clinic visit or in a private room at the clinic. Seminal plasma was used for HIV-1 analysis and the cell component was used for cytomegalovirus (CMV) analysis. Participants also collected daily swabs of genital and perianal skin at home for HSV DNA PCR, as described [3] .
Specimen collection and laboratory procedures
Blood specimens Peripheral blood was collected into tubes containing ethylenediaminetetraacetic acid (Becton Dickinson, Franklin Lakes, New Jersey, USA) and separated within 6 h into plasma and mononuclear cells by Ficoll-Hypaque gradient centrifugation. Lymphocyte subsets were determined by flow cytometry methods in Lima. Plasma aliquots were frozen at À708C and transported to the University of Washington Retrovirology Laboratory. Blood plasma preparation methods have been described previously [3] .
Semen specimens
Within 6 h of collection, vials containing whole semen specimens were frozen at À808C. Semen samples were transported to the University of Washington on dry ice and stored at À808C until tested. Vials were thawed and microcentrifuged at 16 000 Â g for 15 min to separate seminal plasma and cell components. Seminal plasma aliquots (250 ml) were diluted 1 : 5 with Roswell Park Memorial Institute media [11] , and centrifuged for 1 h at 23 000 Â g. The pellets were resuspended in bioMerieux lysis buffer and extracted using the MiniMAG Extraction system, which uses magnetic silica beads based on the Boom Technology (bioMerieux, Durham, North Carolina, USA).
HIV-1 RNA quantitation assays HIV-1 RNA was quantified using an independently validated TaqMan real-time RNA PCR (RT-PCR) amplification assay or the Amplicor HIV Monitor assay (Roche Molecular Systems, Pleasanton, California, USA) [3, 12] . For the TaqMan assay, the lower limit of detection (LLOD) for HIV-1 quantitation in blood plasma was 120 (2.1 log 10 ) HIV-1 RNA copies/ml; for the Amplicor HIV Monitor assay, the LLOD in plasma was 400 (2.6 log 10 ) HIV-1 RNA copies/ml. In semen, LLOD were 300 (2.5 log 10 ) and 800 (2.9 log 10 ) copies/ml for the Taqman realtime PCR or Roche Amplicor Monitor, respectively.
HSV and CMV DNA assays DNA was extracted from each specimen. A fluorescent probe-based RT-PCR (TaqMan; Applied Biosystems, Foster City, California, USA) assay was used to quantitate HSV [3, 13] and CMV levels [14] . LLOD for HSV detection was 2.69 log 10 copies/ml and for CMV detection was 10 copies/ml.
Statistical methods
Herpes simplex virus shedding rate was computed by dividing the days with detectable HSV in swabs collected at home or in the clinic by the total days of swab collection. All analyses were done on an intent-to-treat basis, excluding the first day of study drug administration from each arm. Laboratory testing was performed without knowledge of treatment assignment. For undetectable HIV-1 values, the midpoint between zero and the LLOD was used [15] ; quantitative HIV-1 and CMV values were log-transformed. HSV shedding was examined as a binary variable (detected vs. not detected), as HSV DNA was detected in only a small proportion of samples. Because CMV detection was more common, quantity detected was retained and a sensitivity analysis was performed to examine the influence of the values assigned to amounts below the limit of detection. There was no difference in the outcomes between analyses done with undetectable CMV set to zero vs. when undetectable quantities were set to a random value between 0 and the LLOD.
Linear mixed models were used to examine quantitative differences within participants by treatment arm, using multivariate models to evaluate the effects of co-factors. Because HIV-1 quantity was modeled on the log 10 scale, coefficients from models are exponentiated and compared with 1 to compute percentage change in HIV-1 quantity. Statistical analysis was performed using SAS for Windows (version 9.1; SAS Institute Inc., Cary, North Carolina, USA).
Results
The study population has been described previously [3] , with one participant excluded because of persistent semen assay inhibition, so the analysis included 19 men. The median age was 39 years (range 22-45) and median CD4 cell count was 424 cells/ml (range 232-869). Using adherence data from pill counts conducted every 2 weeks, participants took a median of 97% (range 65.8-100) of pills.
HSV and HIV-1 detection and levels
Overall, HIV-1 was detected at least once in semen samples from all 19 participants and in 71% of 231 semen specimens (Table 1) . HSV was detected in 29 and 4.4% of rectal and anogenital swab specimens from participants on placebo and valacyclovir, respectively (P < 0.001).
Daily valacyclovir suppression reduced the proportion of seminal samples with detectable HIV-1 (63% of samples during valacyclovir vs. 78% during placebo; P ¼ 0.04; Table 1 ) and the quantity of HIV-1 in seminal plasma (Fig. 1) . Mean seminal HIV-1 level (log 10 copies/ml) was 3.19 during valacyclovir and 3.48 during placebo treatment.
In a linear mixed model, the quantity of HIV-1 in semen was 0.25 log 10 lower [95% confidence interval (CI) À0.40 to À0.10; P ¼ 0.001] during the valacyclovir arm compared with placebo, a 44% reduction. The mean seminal HIV-1 level was reduced in 15 participants and increased in four participants during valacyclovir therapy.
Effect of covariates on seminal HIV-1 levels
There was a trend towards an association between plasma HIV-1 RNA and seminal HIV-1 levels (P ¼ 0.07), but the addition of plasma HIV-1 RNA levels to the model minimally changed the effect of valacyclovir on seminal HIV-1 levels (0.29 log 10 decrease in seminal HIV-1 with valacyclovir; 95% CI À0.48 to À0.11; P ¼ 0.002). Undetectable HIV-1 levels were set halfway between zero and the lower limit of detection (LLOD). HSV, herpes simplex virus. a P-value represents comparison between valacyclovir and placebo.
CD4 cell count did not predict seminal HIV-1 levels (P ¼ 0.32). CMV was detected in 111 of 208 tested semen samples and in at least one sample from 11 of 18 men, and was not quantitatively associated with seminal HIV-1 levels (P ¼ 0.68) or administration of valacyclovir (P ¼ 0.68; mean CMV level ¼ 2.3 log 10 on placebo and 2.1 log 10 on valacyclovir).
Discussion
Our study is the first to demonstrate that suppressive valacyclovir reduced seminal HIV-1 levels in HIV-1/ HSV-2 co-infected MSM with intermediate CD4 cell counts not receiving ART. A 0.25 log 10 reduction in HIV-1 levels in semen was observed during multiple time points in each study arm. HSV-2 suppression studies have shown 0.3-0.5 log 10 reductions in plasma HIV-1 levels, and approximately 0.3 log 10 reductions in HIV-1 levels in cervical and rectal secretions [2] [3] [4] [5] . Seminal HIV-1 levels may be an important surrogate for HIV-1 infectiousness and co-factors such as HSV-2 reactivation likely influence HIV-1 infectiousness [10] .
Inclusion of plasma HIV-1 in the linear effects model did not meaningfully alter valacyclovir's effect on HIV-1 shedding. This finding suggests that the association may not be strongly linked to plasma HIV-1 level and that the male genital tract could be a distinct virologic compartment from the blood [16] . An indirect mechanism of HSV-2 suppression on reduction of seminal HIV-1 levels appears most likely as HSV is rarely detected in semen [17] . This mechanism requires further clarification. The dose of valacyclovir used in this study for HSV-2 suppression is significantly lower than the IC 50 for CMV, so we did not anticipate that valacyclovir would suppress CMV. However, given a previous study which indicated that seminal HIV-1 levels were associated with concomitant CMV shedding [18] , we assessed CMV reactivation as a covariate for seminal HIV-1 and did not find an association.
Our study was limited by the fact that we sampled only cell-free seminal plasma for HIV-1 and cellassociated HIV-1 may also be important in HIV-1 transmission. Additionally, we examined only cellassociated CMV as a covariate due to small volumes of seminal samples.
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